{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T23:28:36Z","timestamp":1774999716476,"version":"3.50.1"},"reference-count":32,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes & Metabolic Syndrome: Clinical Research & Reviews"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.dsx.2022.102470","type":"journal-article","created":{"date-parts":[[2022,3,20]],"date-time":"2022-03-20T18:20:05Z","timestamp":1647800405000},"page":"102470","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Hyperlipidemia management in diabetes: First line or supportive therapy?"],"prefix":"10.1016","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8356-3137","authenticated-orcid":false,"given":"Rajeev","family":"Gupta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anoop","family":"Misra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.dsx.2022.102470_bib1","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.4239\/wjd.v6.i13.1246","article-title":"Diabetes and cardiovascular disease: epidemiology, biological mechanisms, treatment recommendations and future research","volume":"6","author":"Leon","year":"2015","journal-title":"World J Diabetes"},{"key":"10.1016\/j.dsx.2022.102470_bib2","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S2213-8587(21)00349-1","article-title":"Diabetes mortality and trends before 25 years of age: an analysis of the global burden of disease study 2019","volume":"10","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.dsx.2022.102470_bib3","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0140-6736(19)31893-8","article-title":"Primary prevention of ischemic heart disease: populations, individuals and healthcare professionals","volume":"394","author":"Gupta","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.dsx.2022.102470_bib4","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1093\/eurheartj\/ehaa099","article-title":"Targeting cardiovascular inflammation: next steps in clinical translation","volume":"42","author":"Lawler","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.dsx.2022.102470_bib5","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/j.cmet.2021.07.001","article-title":"Cardiovascular disease in diabetes, beyond glucose","volume":"33","author":"Eckel","year":"2021","journal-title":"Cell Metabol"},{"key":"10.1016\/j.dsx.2022.102470_bib6","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1016\/S0140-6736(08)60768-0","article-title":"Cardiovascular disease risk in type 2 diabetes mellitus: insights from mechanistic studies","volume":"371","author":"Mazzone","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.dsx.2022.102470_bib7","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood glucose control with sulphonylurea or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)","volume":"352","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.dsx.2022.102470_bib8","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","article-title":"10-year follow-up of intensive glucose control in type 2 diabetes","volume":"359","author":"Holman","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.dsx.2022.102470_bib9","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa0802743","article-title":"Effects of intensive glucose control lowering in type 2 diabetes","volume":"358","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.dsx.2022.102470_bib10","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1056\/NEJMoa0802987","article-title":"Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes","volume":"358","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.dsx.2022.102470_bib11","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJMoa0808431","article-title":"Glucose control and vascular complications in Veterans with type 2 diabetes","volume":"360","author":"Duckworth","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.dsx.2022.102470_bib12","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1007\/s40265-021-01554-6","article-title":"Evolution of type 2 diabetes management from a glucocentric approach to cardio-renal risk reduction: the new paradigm of care","volume":"81","author":"Jacob","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.dsx.2022.102470_bib13","article-title":"AHA\/ACC\/AAACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline of management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on clinical practice guidelines","volume":"139","author":"Grundy","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.dsx.2022.102470_bib14","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"ESC\/EAS guidelines for the management of dyslipidemias: lipid modification to reduce cardiovascular risk: the Task Force for the management of dyslipidemia of the European Society of Cardiology and European Atherosclerosis Society","volume":"41","author":"Mach","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.dsx.2022.102470_bib15","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1016\/j.jacc.2019.03.009","article-title":"ACC\/AHA guideline on the primary prevention of cardiovascular disease","volume":"74","author":"Arnett","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.dsx.2022.102470_bib16","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.dsx.2022.102470_bib17","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0140-6736(04)16895-5","article-title":"Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomized placebo-controlled trial","volume":"364","author":"Colhoun","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.dsx.2022.102470_bib18","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol lowering treatment: prospective meta-analysis of data from 90056 participants in 14 randomized trials of statins","volume":"366","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.dsx.2022.102470_bib19","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(08)60104-X","article-title":"Efficacy of cholesterol lowering therapy in 18686 people with diabetes in 14 randomised trials of statins: a meta-analysis","volume":"371","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.dsx.2022.102470_bib20","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/S0140-6736(14)61368-4","article-title":"Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 267 randomized trials","volume":"385","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.dsx.2022.102470_bib21","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S2213-8587(19)30388-2","article-title":"Intensive LDL cholesterol lowering treatment beyond current recommendations for the prevention of major vascular events: a systematic review and meta-analysis of randomized trials including 327037 participants","volume":"8","author":"Wang","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.dsx.2022.102470_bib22","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","article-title":"Effects of long-erm fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIOELD study): randomised controlled trial","volume":"366","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.dsx.2022.102470_bib23","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s13098-021-00626-7","article-title":"Comparative efficacy of pharmacological agents in reducing the risk of major cardiovascular events in the hypertriglyceridemia population: a network meta-analysis","volume":"13","author":"Qi","year":"2021","journal-title":"Diabetol Metab Syndrome"},{"key":"10.1016\/j.dsx.2022.102470_bib24","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ahj.2018.09.011","article-title":"Rationale and design of the pemafibrate to reduce cardiovascular outcomes by reducing triglycerides in patients with diabetes (PROMINENT) study","volume":"206","author":"Pradhan","year":"2018","journal-title":"Am Heart J"},{"key":"10.1016\/j.dsx.2022.102470_bib25","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1161\/CIRCULATIONAHA.119.041998","article-title":"Association between triglyceride lowering and reduction of cardiovascular risk across multiple lipid-lowering therapeutic classes: a systematic review and meta-regression analysis of randomized controlled trials","volume":"140","author":"Marston","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.dsx.2022.102470_bib26","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"Supp 1","key":"10.1016\/j.dsx.2022.102470_bib27","doi-asserted-by":"crossref","first-page":"4","DOI":"10.2337\/db20-4-LB","article-title":"Substantial cardiovascular benefit from icosapent ethyl in patients with diabetes: REDUCE-IT Diabetes","volume":"69","author":"Bhatt","year":"2020","journal-title":"Diabetes"},{"key":"10.1016\/j.dsx.2022.102470_bib28","doi-asserted-by":"crossref","first-page":"e673","DOI":"10.1161\/CIR.0000000000000709","article-title":"Omega-3 fatty acids for the management of hypertriglyceridemia: a science advisory from the American Heart Association","volume":"140","author":"Skulas-Ray","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.dsx.2022.102470_bib29","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1080\/14779072.2020.1745633","article-title":"The mystery of evacetrapib: why are CETP inhibitors failing?","volume":"18","author":"Nicholls","year":"2020","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"10.1016\/j.dsx.2022.102470_bib30","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S0140-6736(12)60312-2","article-title":"Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomization study","volume":"380","author":"Vioght","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.dsx.2022.102470_bib31","article-title":"Sodium glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials","volume":"372","author":"Palmer","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.dsx.2022.102470_bib32","doi-asserted-by":"crossref","first-page":"e722","DOI":"10.1161\/CIR.0000000000001040","article-title":"Comprehensive management of cardiovascular risk factors for adults with type 2 diabetes: a scientific statement from the American Heart Association","volume":"145","author":"Joseph","year":"2022","journal-title":"Circulation"}],"container-title":["Diabetes & Metabolic Syndrome: Clinical Research & Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871402122000844?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871402122000844?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T09:19:24Z","timestamp":1761729564000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1871402122000844"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["S1871402122000844"],"URL":"https:\/\/doi.org\/10.1016\/j.dsx.2022.102470","relation":{},"ISSN":["1871-4021"],"issn-type":[{"value":"1871-4021","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hyperlipidemia management in diabetes: First line or supportive therapy?","name":"articletitle","label":"Article Title"},{"value":"Diabetes & Metabolic Syndrome: Clinical Research & Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dsx.2022.102470","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Diabetes India. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102470"}}